ISC-17536 is under clinical development by Ichnos Sciences and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect ISC-17536’s likelihood of approval (LoA) and phase transition for Diabetic Neuropathic Pain took place on 10 Aug 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ISC-17536 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
ISC-17536 (GRC-17536) is under development for the treatment of diabetic neuropathic pain. The drug candidate is administered by oral or inhalational route. It is a new chemical entity. The drug candidate targets TRPA1 (Transient receptor potential cation channel subfamily A member 1) receptor. It was under development for respiratory disorders including asthma and chronic cough.
Ichnos Sciences overview
Ichnos Sciences is an US based bio pharmaceutical manufacturing company. The company is engaged in developing therapies for treating oncology and autoimmune disease. It’s technology portfolio includes BETA platform which uses a novel method for engineering bispecific antibodies that may treat cancers.
Quick View ISC-17536 LOA Data
|Highest Development Stage|